The Experts below are selected from a list of 210 Experts worldwide ranked by ideXlab platform
Ketty Peris - One of the best experts on this subject based on the ideXlab platform.
-
Photodynamic therapy for Basal Cell carcinoma
Future Oncology, 2015Co-Authors: Maria Concetta Fargnoli, Ketty PerisAbstract:Topical photodynamic therapy is an effective and safe noninvasive treatment for low-risk Basal Cell carcinoma, with the advantage of an exCellent cosmetic outcome. Efficacy of photodynamic therapy in Basal Cell carcinoma is supported by substantial research and clinical trials. In this article, we review the procedure, indications and clinical evidences for the use of photodynamic therapy in the treatment of Basal Cell carcinoma.
-
Photodynamic therapy for Basal Cell carcinoma
Future Oncology, 2015Co-Authors: Maria Concetta Fargnoli, Ketty PerisAbstract:Topical photodynamic therapy is an effective and safe noninvasive treatment for low-risk Basal Cell carcinoma, with the advantage of an exCellent cosmetic outcome. Efficacy of photodynamic therapy in Basal Cell carcinoma is supported by substantial research and clinical trials. In this article, we review the procedure, indications and clinical evidences for the use of photodynamic therapy in the treatment of Basal Cell carcinoma.
Philip R. Cohen - One of the best experts on this subject based on the ideXlab platform.
-
Red Dot Basal Cell Carcinoma: Literature Review of a Unique Clinical Subtype of Basal Cell Carcinoma
Dermatology and Therapy, 2021Co-Authors: Philip R. Cohen, Marta Torres-quiñones, Nathan S. UebelhoerAbstract:Red dot Basal Cell carcinoma is a distinctive clinical subtype of Basal Cell carcinoma. It has been reported in eight individuals with a male to female ratio of 1:1; and the patients’ ages ranged from 50 to 74 years. All patients had prior history of actinic keratoses and Basal Cell carcinoma. In addition, some patients also had prior squamous Cell carcinoma, malignant melanoma, and/or dysplastic nevus. The tumor was usually of recent onset, asymptomatic, and on sun-exposed skin. It was most commonly located on the nose (five patients); other sites were the upper lip, the mid back, or thigh—each in one patient. The red dot Basal Cell carcinoma was solitary and small—usually 4 mm or less in diameter. It typically presented as a red macule or papule; however, it sometimes appeared as a flesh-colored or pink to light-red papule with a bright-red central area. Microscopic features showed Basaloid tumor Cells (arranged as either nodular aggregates or superficial buds or both). In the central portion of the lesion, there was a proliferation of erythrocyte-containing vascular spaces between the epidermis and the neoplasm. The Basal Cell carcinoma pathology subtype was either nodular and superficial (three patients), nodular (two patients), or superficial (one patient). The clinical differential diagnosis of red dot Basal Cell carcinoma included not only benign vascular lesions (such as hemangioma and telangiectasia) but also inflammatory conditions and adnexal tumors. Other Basaloid Cell neoplasms were in the pathologic differential diagnosis. The pathogenesis of red dot Basal Cell carcinoma is similar to that of other Basal Cell carcinoma clinical subtypes. Mohs surgery is the treatment of choice for red dot Basal Cell carcinomas. Red dot Basal Cell carcinoma has two categories of biologic behavior based on the ratio of the postoperative wound size as compared with the size of the preoperative tumor: nonaggressive (for which the ratio was 5:1 or less for three patients) and aggressive (for which the ratio was greater than 12:1 for three patients). There was no recurrence of the red dot Basal Cell carcinoma after treatment. In conclusion, the incidence of red dot Basal Cell carcinoma—a unique morphologic variant of Basal Cell carcinoma—may be higher than suggested by the number of reported patients with this Basal Cell carcinoma subtype.
-
Basal Cell Carcinoma With Calcification: Case Report of Calcifying Basal Cell Carcinoma and Review of Calcinosis Cutis Associated With Basal Cell Carcinoma.
Cureus, 2021Co-Authors: Parnia Forouzan, Antoanella Calame, Nathan S. Uebelhoer, Philip R. CohenAbstract:Basal Cell carcinoma is the most common cutaneous neoplasm. Calcinosis cutis is the deposition of calcium within the dermis. An 80-year-old man presented with a pearly nodule on his left nasal ala; a shave biopsy confirmed the diagnosis of a nodular Basal Cell carcinoma with calcinosis cutis, which was removed with Mohs micrographic surgery. The incidence of Basal Cell carcinoma with calcinosis cutis as well as the classification, identification, and potential origin of calcium deposits in Basal Cell carcinoma are discussed. Basal Cell carcinoma can be associated with calcinosis cutis; indeed, calcifying Basal Cell carcinoma has a calculated incidence of 14%. There are five categories of calcification in Basal Cell carcinoma. In addition, calcification observed in cancer-free initial sections of a suspected Basal Cell carcinoma may be a diagnostic clue that a neoplasm is present in deeper sections of the tissue specimen. Although nodular Basal Cell carcinoma has the greatest incidence (37%) of calcium deposition, infiltrative (29%) and micronodular (27%) Basal Cell carcinomas are also frequently associated with calcification; therefore, the presence of calcifying Basal Cell carcinoma may indicate a more aggressive tumor subtype. Basal Cell carcinoma may also be suspected in the differential diagnosis of a superficial breast neoplasm in which calcification is observed in the dermis; in this situation, mammography has been an effective diagnostic approach for identifying the Basal Cell carcinoma with calcification. The pathogenesis of calcification in Basal Cell carcinoma remains to be definitively established; however, calcium-binding proteins found in poorly differentiated keratinocytes may contribute to the etiology of Basal Cell carcinoma with calcification. The treatment of Basal Cell carcinomas with calcinosis cutis is similar to that of non-calcifying Basal Cell carcinomas; it is based upon the histologic subtype, the size, and the location of the tumor.
-
Basal Cell Carcinoma of the Buttock.
Skinmed, 2018Co-Authors: Philip R. CohenAbstract:: Basal Cell carcinoma of the buttock is rare, and only 28 patients have been described. An extensive literature search was performed on Basal Cell carcinoma and buttock using the PubMed database. The literature was evaluated, and the characteristics of individuals with Basal Cell carcinoma of the buttock were summarized. The calculated prevalence of Basal Cell carcinoma of the buttock was 0.35%. The majority of patients had no obvious Basal Cell carcinoma-associated risk factors. Carcinomas were observed 1.2 times more often in women than in men, and more often on the right buttock. They frequently presented as an asymptomatic nodule. The buttock tumor was typically associated with a nodular histologic subtype of Basal Cell carcinoma. The prognosis for these patients was exCellent after complete removal of the tumor. In conclusion, Basal Cell carcinoma of the buttock is a rare clinical variant of this type of skin cancer that usually presented as an asymptomatic nodule in an individual who did not have any traditional risk factors for this malignancy. The cancer was typically associated with a nonaggressive histologic subtype. Recurrence or metastasis was not observed after treatment of the primary tumor.
-
Red Dot Basal Cell Carcinoma.
The Journal of clinical and aesthetic dermatology, 2017Co-Authors: Philip R. CohenAbstract:: Red dot Basal Cell carcinoma, a distinctive morphologic variant of Basal Cell carcinoma that presents as a small red macule (dot) or papule, is described on a woman's thigh. A high index of suspicion is necessary to consider the diagnosis since the tumor mimics a telangiectasia or an angioma.
-
Red Dot Basal Cell Carcinoma: Report of Cases and Review of This Unique Presentation of Basal Cell Carcinoma.
Cureus, 2017Co-Authors: Philip R. CohenAbstract:: Red dot Basal Cell carcinoma is a unique variant of Basal Cell carcinoma. Including the three patients described in this report, red dot Basal Cell carcinoma has only been described in seven individuals. This paper describes the features of two males and one female with red dot Basal Cell carcinoma and reviews the characteristics of other patients with this clinical subtype of Basal Cell carcinoma. A 70-year-old male developed a pearly-colored papule with a red dot in the center on his nasal tip. A 71-year-old male developed a red dot surrounded by a flesh-colored papule on his left nostril. Lastly, a 74-year-old female developed a red dot within an area of erythema on her left mid back. Biopsy of the lesions all showed nodular and/or superficial Basal Cell carcinoma. Correlation of the clinical presentation and pathology established the diagnosis of red dot Basal Cell carcinoma. The tumors were treated by excision using the Mohs surgical technique. Pubmed was searched with the keyword: Basal, Cell, cancer, carcinoma, dot, red, and skin. The papers generated by the search and their references were reviewed. Red dot Basal Cell carcinoma has been described in three females and two males; the gender was not reported in two patients. The tumor was located on the nose (five patients), back (one patient) and thigh (one patient). Cancer presented as a solitary small red macule or papule; often, the carcinoma was surrounded by erythema or a flesh-colored papule. Although Basal Cell carcinomas usually do not blanch after a glass microscope slide is pressed against them, the red dot Basal Cell carcinoma blanched after diascopy in two of the patients, resulting in a delay of diagnosis in one of these individuals. Dermoscopy may be a useful non-invasive modality for evaluating skin lesions when the diagnosis of red dot Basal Cell carcinoma is considered. Mohs surgery is the treatment of choice; in some of the patients, the ratio of the area of the postoperative wound to that of the preoperative cancer was greater than 12:1, demonstrating a significant lateral spread of the tumor beyond the observed clinical margins of the neoplasm. In conclusion, in a patient with a personal history of actinic keratosis or nonmelanoma skin cancer, the appearance of a new red dot in a sun-exposed site should prompt additional evaluation of the skin lesion to exclude or establish the diagnosis of red dot Basal Cell carcinoma.
Adeboye O. Osunkoya - One of the best experts on this subject based on the ideXlab platform.
-
MYB-NFIB gene fusion in prostatic Basal Cell carcinoma: clinicopathologic correlates and comparison with Basal Cell adenoma and florid Basal Cell hyperplasia.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology Inc, 2019Co-Authors: Martin J. Magers, Kenneth A. Iczkowski, Rodolfo Montironi, David J. Grignon, Shaobo Zhang, Sean R. Williamson, Ximing J. Yang, Mingsheng Wang, Adeboye O. Osunkoya, Antonio Lopez-beltranAbstract:Prostatic Basal Cell carcinoma is a malignant neoplasm composed of Basaloid Cells forming infiltrative nests and tubules, which may potentially be misdiagnosed as benign Basal Cell proliferations (i.e., florid Basal Cell hyperplasia or Basal Cell adenoma) and also closely resembles adenoid cystic carcinoma of the salivary gland. MYB-NFIB gene rearrangement occurs in 30–86% of salivary gland adenoid cystic carcinomas. We sought to further characterize MYB gene rearrangement in prostatic Basal Cell carcinoma and correlate MYB-NFIB fusion status with other clinicopathologic characteristics. To this end, FISH analysis for MYB-NFIB gene fusion using fusion probes was performed on formalin-fixed, paraffin-embedded tissue sections from prostatic Basal Cell carcinoma (n = 30), florid Basal Cell hyperplasia (n = 18), and Basal Cell adenoma (n = 4). Fourteen of 30 (47%) cases of Basal Cell carcinoma were positive for MYB-NFIB gene fusion FISH, and no cases of benign Basal Cell proliferations were positive (p
-
myb nfib gene fusion in prostatic Basal Cell carcinoma clinicopathologic correlates and comparison with Basal Cell adenoma and florid Basal Cell hyperplasia
Modern Pathology, 2019Co-Authors: Martin J. Magers, Kenneth A. Iczkowski, Rodolfo Montironi, David J. Grignon, Shaobo Zhang, Sean R. Williamson, Ximing J. Yang, Mingsheng Wang, Adeboye O. OsunkoyaAbstract:Prostatic Basal Cell carcinoma is a malignant neoplasm composed of Basaloid Cells forming infiltrative nests and tubules, which may potentially be misdiagnosed as benign Basal Cell proliferations (i.e., florid Basal Cell hyperplasia or Basal Cell adenoma) and also closely resembles adenoid cystic carcinoma of the salivary gland. MYB-NFIB gene rearrangement occurs in 30-86% of salivary gland adenoid cystic carcinomas. We sought to further characterize MYB gene rearrangement in prostatic Basal Cell carcinoma and correlate MYB-NFIB fusion status with other clinicopathologic characteristics. To this end, FISH analysis for MYB-NFIB gene fusion using fusion probes was performed on formalin-fixed, paraffin-embedded tissue sections from prostatic Basal Cell carcinoma (n = 30), florid Basal Cell hyperplasia (n = 18), and Basal Cell adenoma (n = 4). Fourteen of 30 (47%) cases of Basal Cell carcinoma were positive for MYB-NFIB gene fusion FISH, and no cases of benign Basal Cell proliferations were positive (p < 0.05). FISH-positive patients (mean age = 63 years, range: 35-81) tended to be younger than FISH-negative patients (mean age = 70 years, range: 55-93). Most FISH-positive cases demonstrated adenoid cystic carcinoma-like morphology (57%), and most FISH-negative cases demonstrated nonadenoid cystic carcinoma-like morphology (93%); one case (FISH-positive) demonstrated areas with both adenoid cystic carcinoma-like and nonadenoid cystic carcinoma-like morphology. FISH-positive cases more frequently demonstrated perineural invasion (50% vs. 14%, p < 0.05) compared to FISH-negative cases. Conversely, tall Basal Cells (i.e., neoplastic Cells at least two times taller than wide) were more frequent in FISH-negative cases than FISH-positive cases (93% vs. 36%, p < 0.05). Approximately, 50% of prostatic Basal Cell carcinoma harbor MYB-NFIB gene fusion. The majority of these cases were characterized by adenoid cystic carcinoma-like morphology, perineural invasion, and lack tall Basal Cells. Florid Basal Cell hyperplasia and Basal Cell adenoma are negative for MYB-NFIB gene fusion.
Maria Concetta Fargnoli - One of the best experts on this subject based on the ideXlab platform.
-
Photodynamic therapy for Basal Cell carcinoma
Future Oncology, 2015Co-Authors: Maria Concetta Fargnoli, Ketty PerisAbstract:Topical photodynamic therapy is an effective and safe noninvasive treatment for low-risk Basal Cell carcinoma, with the advantage of an exCellent cosmetic outcome. Efficacy of photodynamic therapy in Basal Cell carcinoma is supported by substantial research and clinical trials. In this article, we review the procedure, indications and clinical evidences for the use of photodynamic therapy in the treatment of Basal Cell carcinoma.
-
Photodynamic therapy for Basal Cell carcinoma
Future Oncology, 2015Co-Authors: Maria Concetta Fargnoli, Ketty PerisAbstract:Topical photodynamic therapy is an effective and safe noninvasive treatment for low-risk Basal Cell carcinoma, with the advantage of an exCellent cosmetic outcome. Efficacy of photodynamic therapy in Basal Cell carcinoma is supported by substantial research and clinical trials. In this article, we review the procedure, indications and clinical evidences for the use of photodynamic therapy in the treatment of Basal Cell carcinoma.
Sean R. Williamson - One of the best experts on this subject based on the ideXlab platform.
-
MYB-NFIB gene fusion in prostatic Basal Cell carcinoma: clinicopathologic correlates and comparison with Basal Cell adenoma and florid Basal Cell hyperplasia.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology Inc, 2019Co-Authors: Martin J. Magers, Kenneth A. Iczkowski, Rodolfo Montironi, David J. Grignon, Shaobo Zhang, Sean R. Williamson, Ximing J. Yang, Mingsheng Wang, Adeboye O. Osunkoya, Antonio Lopez-beltranAbstract:Prostatic Basal Cell carcinoma is a malignant neoplasm composed of Basaloid Cells forming infiltrative nests and tubules, which may potentially be misdiagnosed as benign Basal Cell proliferations (i.e., florid Basal Cell hyperplasia or Basal Cell adenoma) and also closely resembles adenoid cystic carcinoma of the salivary gland. MYB-NFIB gene rearrangement occurs in 30–86% of salivary gland adenoid cystic carcinomas. We sought to further characterize MYB gene rearrangement in prostatic Basal Cell carcinoma and correlate MYB-NFIB fusion status with other clinicopathologic characteristics. To this end, FISH analysis for MYB-NFIB gene fusion using fusion probes was performed on formalin-fixed, paraffin-embedded tissue sections from prostatic Basal Cell carcinoma (n = 30), florid Basal Cell hyperplasia (n = 18), and Basal Cell adenoma (n = 4). Fourteen of 30 (47%) cases of Basal Cell carcinoma were positive for MYB-NFIB gene fusion FISH, and no cases of benign Basal Cell proliferations were positive (p
-
myb nfib gene fusion in prostatic Basal Cell carcinoma clinicopathologic correlates and comparison with Basal Cell adenoma and florid Basal Cell hyperplasia
Modern Pathology, 2019Co-Authors: Martin J. Magers, Kenneth A. Iczkowski, Rodolfo Montironi, David J. Grignon, Shaobo Zhang, Sean R. Williamson, Ximing J. Yang, Mingsheng Wang, Adeboye O. OsunkoyaAbstract:Prostatic Basal Cell carcinoma is a malignant neoplasm composed of Basaloid Cells forming infiltrative nests and tubules, which may potentially be misdiagnosed as benign Basal Cell proliferations (i.e., florid Basal Cell hyperplasia or Basal Cell adenoma) and also closely resembles adenoid cystic carcinoma of the salivary gland. MYB-NFIB gene rearrangement occurs in 30-86% of salivary gland adenoid cystic carcinomas. We sought to further characterize MYB gene rearrangement in prostatic Basal Cell carcinoma and correlate MYB-NFIB fusion status with other clinicopathologic characteristics. To this end, FISH analysis for MYB-NFIB gene fusion using fusion probes was performed on formalin-fixed, paraffin-embedded tissue sections from prostatic Basal Cell carcinoma (n = 30), florid Basal Cell hyperplasia (n = 18), and Basal Cell adenoma (n = 4). Fourteen of 30 (47%) cases of Basal Cell carcinoma were positive for MYB-NFIB gene fusion FISH, and no cases of benign Basal Cell proliferations were positive (p < 0.05). FISH-positive patients (mean age = 63 years, range: 35-81) tended to be younger than FISH-negative patients (mean age = 70 years, range: 55-93). Most FISH-positive cases demonstrated adenoid cystic carcinoma-like morphology (57%), and most FISH-negative cases demonstrated nonadenoid cystic carcinoma-like morphology (93%); one case (FISH-positive) demonstrated areas with both adenoid cystic carcinoma-like and nonadenoid cystic carcinoma-like morphology. FISH-positive cases more frequently demonstrated perineural invasion (50% vs. 14%, p < 0.05) compared to FISH-negative cases. Conversely, tall Basal Cells (i.e., neoplastic Cells at least two times taller than wide) were more frequent in FISH-negative cases than FISH-positive cases (93% vs. 36%, p < 0.05). Approximately, 50% of prostatic Basal Cell carcinoma harbor MYB-NFIB gene fusion. The majority of these cases were characterized by adenoid cystic carcinoma-like morphology, perineural invasion, and lack tall Basal Cells. Florid Basal Cell hyperplasia and Basal Cell adenoma are negative for MYB-NFIB gene fusion.
